Azithromycin analogue CSY0073 attenuates lung inflammation induced by LPS challenge

Area of Science:

• Pharmacology
• Immunology
• Pulmonology

Background:

• Azithromycin, a macrolide antibiotic, possesses anti-inflammatory properties beneficial for chronic lung diseases.
• Long-term azithromycin use is linked to adverse effects including antimicrobial resistance and toxicity.

Purpose of the Study:

• To evaluate the anti-inflammatory potential of CSY0073, a non-antibiotic derivative of azithromycin.
• To compare the effects of CSY0073 and azithromycin on inflammation and bacterial growth.

Main Methods:

• Comparative analysis of CSY0073 and azithromycin effects on bacterial cultures and Pseudomonas aeruginosa biofilms.
• In vivo studies using mice models challenged with P. aeruginosa lipopolysaccharide (LPS).
• Assessment of inflammatory markers in bronchoalveolar lavage fluid and lung homogenates.

Main Results:

• CSY0073 exhibited no antibacterial activity against tested pathogens or biofilms, unlike azithromycin.
• Both CSY0073 and azithromycin reduced neutrophil counts and pro-inflammatory cytokines (TNF-α, CXCL1, CXCL2, IL-6, IL-1β) in mouse lung models post-LPS challenge.
• CSY0073 and azithromycin similarly suppressed LPS-induced pro-inflammatory cytokine production in macrophages.

Conclusions:

• CSY0073 possesses significant anti-inflammatory effects comparable to azithromycin.
• The absence of antibacterial activity makes CSY0073 a promising candidate for long-term management of chronic lung conditions.
• CSY0073 may provide therapeutic benefits without the risks associated with antibiotic resistance and toxicity.